NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal third quarter 2023 ended June 30, 2023.
Fiscal Third Quarter 2023 and Recent Business Updates
Financial Highlights
- Product revenue of
$630,000 in Q3 2023, compared to$32,000 in Q3 2022 - Collaboration revenue of
$1.46 million in first nine months of FY 2023, compared to$6,000 in first nine months of FY 2022 - Operating cash burn reduction expected with the completion of development of the OneRF™ Ablation System beginning in Fiscal Q4 2023
Evo® sEEG:
- Completed limited launch at target centers by end of July; full launch with Zimmer Biomet expected by end of fiscal fourth quarter
- Positive user feedback received on product evaluation forms
- Initiation of new sites expected to ramp in fiscal fourth quarter
- Received first order for calendar 2024 product supply from Zimmer Biomet
OneRF™Ablation:
- Submitted 510(k) to FDA on June 8th
- Poster presentation on OneRF Ablation System preclinical study at the Neurological Disorders Summit (NDS 2023) in Italy
- Received feedback from FDA regarding 510(k) submission for OneRF Ablation System
Spinal Cord Stimulation Program:
- Completed 28 day animal implants of the Company’s thin film spinal cord stimulation paddle electrodes without any adverse events or neurological complications
- Filed a non-provisional patent for a novel conformable thin film paddle lead for spinal cord placement
Drug Delivery Program:
- Successfully completed proof of concept testing of drug delivery into the brain in a small animal model at the Mayo Clinic in Rochester, Minnesota
Dave Rosa, CEO of NeuroOne, commented, “The Company continues to execute on a number of commercial, development and financing objectives. We are now beginning to expand the commercial launch of our Evo sEEG electrode with Zimmer Biomet after a successful limited launch. In addition, we received encouraging feedback from the FDA regarding the Company’s recent 510(k) FDA submission of the OneRF Ablation System and believe our previous timelines remain on track. We are excited by the potential of our drug delivery system currently in development after recent testing at the Mayo Clinic in Rochester Minnesota. We also recently raised gross proceeds of
Upcoming Targeted Milestones
Evo sEEG:
- Full market launch of Evo sEEG system with Zimmer Biomet
- Expand sales training of the sEEG product line to Zimmer personnel
OneRF Ablation:
- Poster presentation planned for the Congress of Neurological Surgeons (CNS) Meeting in September
- Initiate component orders for OneRF ablation system for future commercialization
SCS Program:
- Complete testing of an implantable pulse generator (IPG) for fluid ingress
- Perform percutaneous placement of a paddle electrode in a human cadaver model
Drug Delivery Program:
- Define product requirements for drug delivery system for both clinical and research use in the biotech and pharma industry
- Complete large animal feasibility studies for drug delivery system into the brain.
Fiscal Third Quarter 2023 Financial Results
Product revenue was
Total operating expenses in the fiscal third quarter 2023 were
Net loss was
As of June 30, 2023, the Company had cash and cash equivalents of
On July 27, 2023, the Company consummated an underwritten public offering of its common stock from which the Company received
The Company had no debt outstanding as of June 30, 2023.
Conference Call and Webcast Information
Monday, August 14, 2023 – 4:30 PM Eastern Time
Participant Dial-In:
800-267-6316/+1 203-518-9783
Conference ID (required for entry): NEURO
Live Webcast:
Join here.
Phone Replay:
877-660-6853 / 201-612-7415,
Available through August 28, 2023
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the development of the Company's electrode technology program, applications for, or receipt of, regulatory clearance, the timing and extent of product launch and commercialization of our technology, receipt of revenues from sale of the sEEG electrodes, timing and success of any clinical and pre-clinical testing, development of our OneRF, SCS and drug delivery programs, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, the impact of COVID-19 or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
Contact:
800-631-4030
NeuroOne Medical Technologies Corporation
Condensed Balance Sheets
(unaudited)
| June 30, 2023 | September 30, 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,083,458 | $ | 8,160,329 | ||||
| Short-term investments | — | 2,981,010 | ||||||
| Accounts receivable | — | 33,237 | ||||||
| Inventory | 1,516,527 | 704,538 | ||||||
| Prepaids and other | 278,786 | 296,649 | ||||||
| Total current assets | 4,878,771 | 12,175,763 | ||||||
| Intangible assets, net | 95,156 | 111,892 | ||||||
| Right-of-use asset | 197,324 | 181,355 | ||||||
| Property and equipment, net | 586,873 | 353,599 | ||||||
| Total assets | $ | 5,758,124 | $ | 12,822,609 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 958,811 | $ | 927,662 | ||||
| Accrued expenses and other liabilities | 789,097 | 715,839 | ||||||
| Deferred revenue | — | 1,455,188 | ||||||
| Total current liabilities | 1,747,908 | 3,098,689 | ||||||
| Operating lease liability, long term | 88,918 | 119,556 | ||||||
| Total liabilities | 1,836,826 | 3,218,245 | ||||||
| Commitments and contingencies (Note 4) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 17,862 | 16,217 | ||||||
| Additional paid–in capital | 63,454,618 | 60,414,959 | ||||||
| Accumulated deficit | (59,551,182 | ) | (50,826,812 | ) | ||||
| Total stockholders’ equity | 3,921,298 | 9,604,364 | ||||||
| Total liabilities and stockholders’ equity | $ | 5,758,124 | $ | 12,822,609 | ||||
See accompanying notes to condensed financial statements
NeuroOne Medical Technologies Corporation
Condensed Statements of Operations
(unaudited)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Product revenue | $ | 629,906 | $ | 32,049 | $ | 1,210,661 | $ | 102,381 | ||||||||
| Cost of product revenue | 386,240 | 38,462 | 947,799 | 158,113 | ||||||||||||
| Product gross profit (loss) | 243,666 | (6,413 | ) | 262,862 | (55,732 | ) | ||||||||||
| Collaborations revenue | — | — | 1,455,188 | 6,374 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 1,862,389 | 1,529,670 | 5,347,234 | 5,090,018 | ||||||||||||
| Research and development | 1,891,512 | 1,225,351 | 5,161,322 | 3,491,193 | ||||||||||||
| Total operating expenses | 3,753,901 | 2,755,021 | 10,508,556 | 8,581,211 | ||||||||||||
| Loss from operations | (3,510,235 | ) | (2,761,434 | ) | (8,790,506 | ) | (8,630,569 | ) | ||||||||
| Other income, net | 41,462 | 1,707 | 66,136 | 5,300 | ||||||||||||
| Loss before income taxes | (3,468,773 | ) | (2,759,727 | ) | (8,724,370 | ) | (8,625,269 | ) | ||||||||
| Provision for income taxes | — | — | ||||||||||||||
| Net loss | $ | (3,468,773 | ) | $ | (2,759,727 | ) | $ | (8,724,370 | ) | $ | (8,625,269 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.20 | ) | $ | (0.17 | ) | $ | (0.52 | ) | $ | (0.54 | ) | ||||
| Number of shares used in per share calculations: | ||||||||||||||||
| Basic and diluted | 17,578,871 | 16,193,442 | 16,740,546 | 15,927,734 | ||||||||||||
See accompanying notes to condensed financial statements
